Home  |  Contact

Cellosaurus NK-92MIhCD16 (CVCL_JX95)

[Text version]

Cell line name NK-92MIhCD16
Accession CVCL_JX95
Resource Identification Initiative To cite this cell line use: NK-92MIhCD16 (RRID:CVCL_JX95)
Comments Characteristics: Transfected with the CD16-BB-zeta construct that consist of a signal peptide, the FCGR3/CD16A extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD3Z signaling domain.
Transfected with: HGNC; 3619; FCGR3A (extracellular domain).
Transfected with: HGNC; 6001; IL2.
Caution: NantKwest exclusively owns, controls and distributes NK-92MI. This CD16-modified variant of NK-92MI was created by a research group and is governed by a Material Transfer Agreement that prevents them from legally distributing the cells to any third party.
Derived from sampling site: Peripheral blood.
Disease Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_3755 (NK-92MI)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line

PubMed=28415754; DOI=10.18632/oncotarget.16201
Chen Y., You F.-T., Jiang L.-C., Li J.-L., Zhu X.J., Bao Y.-Y., Sun X., Tang X.-W., Meng H.-M., An G.-L., Zhang B.-Z., Yang L.
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-zeta or CD64-BB-zeta receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Oncotarget 8:37128-37139(2017)

Other Wikidata; Q54930659
Entry history
Entry creation22-Aug-2017
Last entry updated07-Sep-2018
Version number3